{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:25:42Z","timestamp":1790414742012,"version":"4.1.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Ann Plast Surg"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Raynaud phenomenon (RP) is a vasospastic condition of the digits that can be primary or secondary to systemic disease. Symptoms are triggered by cold or stress and can cause pain and skin color changes. The chronic ischemia may lead to necrosis, ulceration, and amputation. There are no Food and Drug Administration\u2013approved treatments and cases refractory to pharmacologic and surgical treatments are difficult to control. Local botulinum toxin injections have been increasingly used in the treatment of Raynaud disease and have shown promising results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim of the study<\/jats:title>\n            <jats:p>To examine the outcomes, techniques, and complications of botulinum toxin use for the treatment of Raynaud disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The PubMed database was queried using \u201cbotulinum toxin\u201d AND \u201cRaynaud phenomenon\u201d as title key words. Preferred reporting items for systematic reviews and meta-analysis criteria were used. Additional articles were selected while reviewing the references of the articles from PubMed. No time restrictions were followed. Articles of all languages were included. Articles were analyzed for study type, demographics, diagnosis\/inclusion criteria, treatment methods, outcome measures, length of follow-up, results, and complications. A positive outcome was defined as subjective improvement in symptoms and\/or improvement in the outcome measures. A poor outcome was defined as harm done to the patient by the injection that would not have occurred otherwise.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Forty-two clinical studies describing the use of botulinum toxin for Raynaud's phenomenon were found. A total of 425 patients with primary or secondary Raynaud's were treated, with ages ranging from 14 to 91 years. There were 342 women and 81 men, with a female-to-male ratio of 38:9. Outcomes were positive in 96.2% of patients. There were 14.2% of the studies that reported 3.5% of all patients showing no subjective improvement. A single study reported a poor outcome for 1 patient. There were 40.5% of the studies that reported complications, affecting 20.2% of all patients. The most frequently reported complication was transient hand weakness, affecting 44.2% of patients with complications and 8.9% of total patients. Weakness resolved in hours to months after injection. Pain at the injection site lasting minutes to days was reported in 40.7% of patients with complications, and 8.2% of total patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Botulinum toxin treatment for RP is effective. Complications are minor and self-limiting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/sap.0000000000003603","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T21:12:49Z","timestamp":1689369169000},"page":"159-186","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["The Use of Botulinum Toxin in Raynaud Phenomenon"],"prefix":"10.1097","volume":"91","author":[{"given":"Olivia","family":"Lawson","sequence":"first","affiliation":[{"name":"University of Tennessee Health Science Center, College of Medicine, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Konofaos","sequence":"additional","affiliation":[{"name":"Division of Plastic Surgery, Department of Surgery, University of Texas Medical Branch, Galveston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250616","first-page":"E11","article-title":"Botulinum toxin for the treatment of intractable Raynaud phenomenon","volume":"108","year":"2021","journal-title":"Cutis"},{"key":"bib2-20250616","first-page":"e12511","article-title":"Use of botulinum toxin a to treat chemotherapy-induced Raynaud's phenomenon","volume":"13","year":"2021","journal-title":"Cureus"},{"key":"bib3-20250616","first-page":"580","article-title":"Raynaud's phenomenon","volume":"20","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"bib4-20250616","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.prs.0000244860.00674.57","article-title":"Management of vasospastic disorders with botulinum toxin a","volume":"119","year":"2007","journal-title":"Plast Reconstr Surg"},{"key":"bib5-20250616","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1177\/15385744211005663","article-title":"Novel combined approach for digital necrosis secondary to Raynaud's phenomenon","volume":"55","year":"2021","journal-title":"Vasc Endovascular Surg"},{"key":"bib6-20250616","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.36849\/JDD.6135","article-title":"OnabotulinumtoxinA for systemic sclerosis-associated Raynaud's phenomenon: a multi-institutional study on accessibility and effectiveness","volume":"20","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"bib7-20250616","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.semarthrit.2011.07.006","article-title":"Botulinum toxin a treatment of Raynaud's phenomenon: a review","volume":"41","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"bib8-20250616","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","year":"2015","journal-title":"Syst Rev"},{"key":"bib9-20250616","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2362.2004.01324.x","article-title":"Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study","volume":"34","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"bib10-20250616","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2310\/7750.2008.07044","article-title":"Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type a treatment","volume":"12","year":"2008","journal-title":"J Cutan Med Surg"},{"key":"bib11-20250616","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhsa.2008.11.026","article-title":"Botulinum toxin type a: a treatment option for digital ischemia in patients with Raynaud's phenomenon","volume":"34","year":"2009","journal-title":"J Hand Surg Am"},{"key":"bib12-20250616","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/PRS.0b013e3181a80576","article-title":"Botox therapy for ischemic digits","volume":"124","year":"2009","journal-title":"Plast Reconstr Surg"},{"key":"bib13-20250616","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.jhsa.2010.09.019","article-title":"Botulinum toxin type a in the treatment of Raynaud's phenomenon","volume":"35","year":"2010","journal-title":"J Hand Surg Am"},{"key":"bib14-20250616","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archdermatol.2011.1144","article-title":"Botulinum toxin-a for the treatment of Raynaud syndrome","volume":"148","year":"2012","journal-title":"Arch Dermatol"},{"key":"bib15-20250616","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jaad.2013.06.029","article-title":"A pilot study evaluating the efficacy of botulinum toxin a in the treatment of Raynaud phenomenon","volume":"69","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"bib16-20250616","first-page":"658","article-title":"Botulinum toxin type a contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis","volume":"58","year":"2013","journal-title":"Ann Chir Plast Esthet"},{"issue":"6\u20137","key":"bib17-20250616","first-page":"462","article-title":"Improvement of idiopathic Raynaud's phenomenon following local infusion of botulinum toxin","volume":"141","year":"2014","journal-title":"Ann Dermatol Venereol"},{"key":"bib18-20250616","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/1753193413516242","article-title":"A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma","volume":"39","year":"2014","journal-title":"J Hand Surg Eur Vol"},{"key":"bib19-20250616","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10072-015-2084-6","article-title":"Treatment of Raynaud's phenomenon with botulinum toxin type a","volume":"36","year":"2015","journal-title":"Neurol Sci"},{"key":"bib20-20250616","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/ajd.12326","article-title":"Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type a treatment","volume":"56","year":"2015","journal-title":"Australas J Dermatol"},{"key":"bib21-20250616","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/RHU.0000000000000450","article-title":"Iatrogenic Thenar Eminence atrophy after Botox a injection for secondary Raynaud phenomenon","volume":"22","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"bib22-20250616","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1346-8138.13030","article-title":"Beneficial effect of botulinum toxin a on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study","volume":"43","year":"2016","journal-title":"J Dermatol"},{"key":"bib23-20250616","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/rheumatology\/kew225","article-title":"Management of Raynaud's digital ulcer with interdigital botulinum toxin a injection","volume":"55","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"bib24-20250616","doi-asserted-by":"crossref","first-page":"e5092","DOI":"10.1097\/MD.0000000000005092","article-title":"A case report of the beneficial effects of botulinum toxin type a on Raynaud phenomenon in a patient with lung cancer","volume":"95","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"bib25-20250616","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.40123","article-title":"The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, Placebo-Controlled Clinical Trial","volume":"69","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"bib26-20250616","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2340\/00015555-2665","article-title":"Efficacy of botulinum toxin B injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis","volume":"97","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"bib27-20250616","first-page":"13030\/qt9zr1318w","article-title":"Botulinum toxin for treatment of Raynaud phenomenon in CREST syndrome","volume":"24","year":"2018","journal-title":"Dermatol Online J"},{"key":"bib28-20250616","article-title":"The novel use of botulinum toxin a for the treatment of Raynaud's phenomenon in the toes","volume":"2018","year":"2018","journal-title":"BMJ Case Rep"},{"key":"bib29-20250616","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/ced.13333","article-title":"Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin","volume":"43","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"bib30-20250616","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5152\/eurjrheum.2018.18013","article-title":"Botulinum toxin type a in the treatment of Raynaud's phenomenon: a three-year follow-up study","volume":"5","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"bib31-20250616","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/1346-8138.14140","article-title":"Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary","volume":"45","year":"2018","journal-title":"J Dermatol"},{"key":"bib32-20250616","first-page":"943","article-title":"Botulinum toxin in the long-term treatment of refractory Raynaud's phenomenon","volume":"18","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"bib33-20250616","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/SAP.0000000000001622","article-title":"Botulinum toxin injection for lower face and Oral cavity Raynaud phenomenon after Mandibulectomy, free fibula reconstruction, and radiation therapy","volume":"82","year":"2019","journal-title":"Ann Plast Surg"},{"key":"bib34-20250616","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s10067-019-04762-4","article-title":"Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series","volume":"38","year":"2019","journal-title":"Clin Rheumatol"},{"key":"bib35-20250616","first-page":"e14182","article-title":"Botulinum toxin type a in the treatment of Raynaud's phenomenon","volume":"33","year":"2020","journal-title":"Dermatol Ther"},{"issue":"6S Suppl 5","key":"bib36-20250616","first-page":"S386","article-title":"The Use of Ultrasound Guidance for the Treatment of Raynaud Disease of the Hand With Botulinum Toxin","volume":"84","year":"2020","journal-title":"Ann Plast Surg"},{"key":"bib37-20250616","first-page":"e8235","article-title":"The effect of Abobotulinum toxin a on the symptoms of Raynaud's phenomenon: a case series","volume":"12","year":"2020","journal-title":"Cureus"},{"key":"bib38-20250616","article-title":"BTX-A Promotes Expression of Angiogenesis-Associated Genes in Human Umbilical Vein Endothelial Cells","year":"2020","journal-title":"DNA Cell Biol"},{"key":"bib39-20250616","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/DSS.0000000000002397","article-title":"Botulinum toxin a treatment for primary and secondary Raynaud's phenomenon in teenagers","volume":"47","year":"2021","journal-title":"Dermatol Surg"},{"key":"bib40-20250616","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/23971983211034077","article-title":"Is axillary botulinum toxin efficient in controlling secondary Raynaud's phenomenon? A case report","volume":"6","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"bib41-20250616","doi-asserted-by":"crossref","first-page":"513.e1","DOI":"10.1016\/j.jhsa.2020.11.005","article-title":"The Effects of Botulinum Toxin A on Pain in Ischemic Vasospasm","volume":"46","year":"2021","journal-title":"J Hand Surg Am"},{"key":"bib42-20250616","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00296-020-04606-4","article-title":"Targeted high concentration botulinum toxin a injections in patients with Raynaud's phenomenon: a retrospective single-Centre experience","volume":"41","year":"2021","journal-title":"Rheumatol Int"},{"key":"bib43-20250616","first-page":"e15529","article-title":"The efficacy of botulinum toxin A in the treatment of Raynaud's phenomenon in systemic sclerosis: A randomized self-controlled trial","volume":"35","year":"2022","journal-title":"Dermatol Ther"},{"key":"bib44-20250616","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/1573397117666211012105611","article-title":"Evaluation of botulinum toxin type a and its potential effect on exacerbated Raynaud's phenomenon in hospitalized scleroderma patients","volume":"18","year":"2022","journal-title":"Curr Rheumatol Rev"},{"key":"bib45-20250616","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10067-021-05900-7","article-title":"A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-a vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis","volume":"41","year":"2022","journal-title":"Clin Rheumatol"},{"key":"bib46-20250616","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/pde.14160","article-title":"Ischemic ulcers of the toes secondary to Raynaud's phenomenon in a child successfully treated with botulinum toxin","volume":"37","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"bib47-20250616","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon","volume":"46","year":"2002","journal-title":"Arthritis Rheum"},{"key":"bib48-20250616","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0363-5023(10)80065-6","article-title":"The measurement of cold sensitivity of the hand","volume":"16","year":"1991","journal-title":"J Hand Surg Am"},{"key":"bib49-20250616","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1088\/0967-3334\/28\/3\/R01","article-title":"Photoplethysmography and its application in clinical physiological measurement","volume":"28","year":"2007","journal-title":"Physiol Meas"},{"key":"bib50-20250616","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"bib51-20250616","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.det.2014.06.012","article-title":"Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis","volume":"32","year":"2014","journal-title":"Dermatol Clin"},{"key":"bib52-20250616","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3390\/toxins4111196","article-title":"Emerging opportunities for serotypes of botulinum neurotoxins","volume":"4","year":"2012","journal-title":"Toxins (Basel)"},{"issue":"Pt A","key":"bib53-20250616","first-page":"77","article-title":"Clinical differences between botulinum neurotoxin type A and B","volume":"107","year":"2015","journal-title":"Toxicon"},{"key":"bib54-20250616","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhsa.2012.01.021","article-title":"The effect of botulinum neurotoxin-a on blood flow in rats: a potential mechanism for treatment of Raynaud phenomenon","volume":"37","year":"2012","journal-title":"J Hand Surg Am"},{"key":"bib55-20250616","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2147\/DDDT.S161113","article-title":"The mechanism of botulinum a on Raynaud syndrome","volume":"12","year":"2018","journal-title":"Drug Des Devel Ther"}],"container-title":["Annals of Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SAP.0000000000003603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T23:08:02Z","timestamp":1750115282000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SAP.0000000000003603"}},"subtitle":["A Comprehensive Literature Review"],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/sap.0000000000003603","relation":{},"ISSN":["1536-3708","0148-7043"],"issn-type":[{"value":"1536-3708","type":"electronic"},{"value":"0148-7043","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}